diagnosis faster News
-
Showcase
Neeuro (Singapore) and epihunter (Belgium) partner to create new and innovative digital solutions for people with brain disorders
On March 15th 2015, Tim Buckinx’ son said: “Papa, you work in digital, can’t you create a light that turns on when my brain switches off?” At ten years old, he was simply fed up with the daily impact of his refractory epilepsy. That pain became a vision, and that vision became the Belgian digital therapeutics company epihunter, aimed at enabling people with a brain ...
By Epihunter NV
-
Fusion Genomics Receives $1 Million from CQDM To Study ONETest RTI Assay
We are pleased to share the news that Fusion Genomics has received a $1 million award to conduct a study evaluating our comprehensive, novel ONETest PathoGenome assay for the detection of pathogens associated with respiratory tract infections (RTIs). Due in great part to limitations associated with current diagnostic tests, RTIs are a leading cause of morbidity, mortality, and hospitalizations ...
-
LKC Technologies Announces Brazilian Health Regulatory Agency Approval for the UTAS™ System
LKC Technologies is pleased to announce that the Brazilian Health Regulatory Agency (Anvisa) has granted approval of the UTAS® device, making this a significant advancement in the preservation and enhancement of sight for patients in Brazil. LKC is collaborating with Oculus Brasil to provide physicians with broader access to LKC’s UTAS System and RETeval devices. Both are in extensive ...
-
Biotricity now taking pre-orders for its Biotres wireless wearable cardiac monitoring device
Announcement follows FDA clearance Pre-Orders begin on February 23, 2022 with units shipping April 1, 2022 Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, today announced that it is now taking pre-orders for Biotres, the Company’s three-lead device designed to continuously record ...
-
Pancreatic Cancer Patients Will Now Have Remote Access to Precision Nutrition Trial Through New Partnership
xCures, Inc. is proud to partner with Vault Health, a decentralized research and workforce screening company, to facilitate the enrollment of pancreatic cancer patients in Faeth Therapeutics’ NEAAR-001 research study. NEAAR-001 is a clinical trial of a precision nutrition-based diet that restricts specific amino acids that preclinical studies suggest are necessary for cancer growth. The ...
By xCures
-
Contraline Secures $10.7M Series A
Contraline, Inc., a venture-backed medical device company devoted to providing men and couples with long-lasting, safe, and effective male contraception, has closed $10.7 million in its Series A financing. The financing round was led by MBX Capital, a venture capital firm that invests in early-stage healthcare and life sciences companies. Additional investors in Contraline include: Rhia ...
-
Major clinical study shows Virusight’s SpectraLIT instantly detects COVID-19 with 96.3% accuracy
Virusight Diagnostic, a world leader in combining artificial intelligence software and spectral technology today announced the results of a major clinical study that found its ultra-rapid, point of care Pathogens Diagnostic solution consistently delivers 96.3% accuracy when compared to the gold standard RT-PCR. The study was conducted by the Department of Science and Technology, University of ...
By Virusight
-
Kephera Diagnostics’ new CLIA laboratory launches testing for COVID-19 antibodies
Kephera Diagnostics announced today that it has been approved as a CLIA certified laboratory by the Massachusetts Dept of Public Health and the U.S. Centers for Medicare and Medicaid, and is now offering COVID-19 antibody testing in Massachusetts and 44 other states. Kephera will use an ELISA (Enzyme-Linked Immunosorbent Assay) test that it developed in-house, which is based on the ...
-
Kephera Diagnostics launches CLIA test for quantitative antibody response to COVID-19 vaccination
Kephera Diagnostics announced today the launch of a quantitative test to measure the level of antibodies elicited by vaccination against COVID-19, as well as by COVID-19 infection. The test will be available as a service through Kephera’s CLIA-certified laboratory. Kephera’s COVI-QUANT™ test measures the level of IgG antibodies to the spike protein, a viral component which is ...
-
FDA grants Breakthrough Device Designation for the Manus NeuroMotor Pen™
Manus Neurodynamica Limited (“Manus”), which develops and markets products and technologies for neuromotor assessment, announces that it has been granted Breakthrough Designation by the U.S. Food and Drug Administration (“FDA”) for its Neuro-Motor PenTM (“NMP”) device. Breakthrough Designation has been granted for the proposed indication of using the ...
-
NIAID awards Phase I contract to Kephera Diagnostics for the development of a new test for Chagas disease
The National Institute of Allergy and Infectious Diseases (NIAID), an agency of the National Institutes of Health (NIH), has awarded a Phase I, $300,000 Small Business Innovative Research (SBIR) contract to Kephera Diagnostics to develop a new test for Chagas disease, the company announced today. The contract, awarded in response to a targeted solicitation from NIAID aimed at improving ...
-
Kephera Diagnostics receives Phase II contract from the National Cancer Institute for a test for liver fluke, an exotic parasite linked to bile duct cancer
Kephera Diagnostics has been awarded a $1,999,961 million Phase II Small Business Innovative Research (SBIR) contract by the National Cancer Institute, an agency of the National Institutes of Health, for a test for liver fluke infection, the Company announced today. Kephera had previously received a $300,000 Phase I contract to develop and demonstrate the feasibility of its test. Liver flukes ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you